Personalized Hemodynamic Management in High-risk Major Abdominal Surgery (PELICAN)
Cardiac Output, Surgery, Postoperative Complications
About this trial
This is an interventional treatment trial for Cardiac Output
Eligibility Criteria
Inclusion Criteria: Consenting patients ≥45 years scheduled for elective major abdominal surgery under general anesthesia that is expected to last ≥90 minutes AND presence of ≥1 of the following high-risk criteria: exercise tolerance <4 metabolic equivalents as defined by the guidelines of the American College of Cardiology/American Heart Association renal impairment (serum creatinine ≥1.3 mg dL-1 or estimated glomerular filtration rate <90 mL min-1 (1.73 m2)-1 within the last 6 months coronary artery disease chronic heart failure (New York Heart Association Functional Classification ≥II) valvular heart disease (moderate or severe) history of stroke peripheral arterial occlusive disease (any stage) chronic obstructive pulmonary disease (any stage) or pulmonary fibrosis (any stage) diabetes mellitus requiring oral hypoglycemic agent or insulin immunodeficiency due to a disease (e.g., HIV, leukemia, multiple myeloma) or therapy (e.g., immunosuppressants, chemotherapy, radiation, steroids [above Cushing threshold]) liver cirrhosis (any Child-Pugh class) body mass index ≥30 kg m-2 history of smoking within two years of surgery age ≥65 years expected anesthesia duration ≥180 minutes B-type natriuretic peptide (BNP) >80 ng/L or N-terminal B-type natriuretic peptide (NT-proBNP) >200 ng/L within the last 6 months Exclusion Criteria: emergency surgery planned surgery: nephrectomy, liver or kidney transplantation surgery status post transplantation of kidney, liver, heart, or lung sepsis (according to current Sepsis-3 definition) American Society of Anesthesiologists physical status classification V or VI pregnancy impossibility of preoperative baseline cardiac index assessment using bioreactance impossibility to perform cardiac index monitoring using the Starling Fluid Management System (Baxter, Deerfield, IL, USA) current participation in another clinical trial or treatment with a similar biological mechanism or primary outcome measure
Sites / Locations
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Routine hemodynamic management (control)
Personalized hemodynamic management (intervention)
In patients assigned to routine hemodynamic management, hemodynamic management will performed as per anesthesiologist preference. Cardiac index monitoring will be will measured using the Baxter Starling Fluid Management System (Baxter, Deerfield, IL, USA). The attending anesthesiologist will be blinded to cardiac index measurements. Cardiac index monitoring can be unblinded upon request. Mean arterial blood pressure will be maintained above 65 mmHg.
In patients assigned to personalized hemodynamic management, intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index measured the day before surgery using a predefined treatment algorithm. Preoperative baseline cardiac index will be determined at least one day before surgery with the patient being awake and resting in supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2). Mean arterial blood pressure will be maintained above 65 mmHg. The study intervention will start at the beginning of surgery and will end at the end of surgery.